



BAUS SECTION OF ONCOLOGY MEETING

EAST MIDLANDS
CONFERENCE CENTRE
NOTTINGHAM

14-15 NOVEMBER 2024



GENERAL INFORMATION

Address

East Midlands Conference Centre, Beeston Lane, Nottingham,
NG7 2RJ

.

Access

The Conference will be held in the Banqueting Suite. The exhibition and refreshments will take place in the Exhibition Hall. Registration and Poster Display will be located in the Concourse.

.

Badges

All delegates, speakers, exhibitors and staff should wear their badge for security reasons during the meeting. Access to the conference and exhibition may be denied to people not wearing badges.

Car Parking

Complimentary car parking is available onsite and limited to 200 spaces.

Directions to East Midlands Conference Centre

Nearest stations are:

Beeston Station (6 minute drive/ 25 minute walk)

Nottingham Railway Station (12 minute drive)

GENERAL INFORMATION

CME Points

The following CME Points will be available for this meeting:

14th November – 6 Points

15th November – 6 Points

Conference Sessions

The Conference will be held in the Banqueting Suite.

.

Exhibition

The BAUS Section of Oncology is delighted to received support from our trade partners and we hope you take the opportunity to visit their stands.

Facilities

Toilets are located on the ground floor.

Paper and Poster Abstracts

Poster Display will be located in the Concourse.

Refreshments

Refreshments will take place in the Exhibition Hall. Any delegate who has advised the BAUS Office in advance of any dietary requirements will find that these have been catered for.

GENERAL INFORMATION

Registration Desk

The registration desk will be open from the following times:

14th November – 0845

15th November – 0830

Social Activities

The conference dinner will take place on 14th November at Browns Nottingham. Tickets can be purchased via the online registration site.

Wi-Fi

Free Wi-Fi will be available throughout the venue

This is promotional material intended for UK HCPs only



BCG-medac's stability of supply enables 3-year maintenance for appropriate high-risk NMIBC patients^{1,2}

BCG-medac is indicated for:

- the treatment of primary or concurrent carcinoma-in-situ of the urinary bladder
- the prevention of recurrence of high-risk non-muscle invasive urothelial bladder

carcinoma (pTaG3, pT1G2, pT1G3) after transurethral resection

- the treatment and/or the prevention of recurrence of aggressive variants of urothelial carcinoma, for example micropapillary or nested variants.

[Click here](#) for full BCG-medac prescribing information and please refer to full SmPC before prescribing.



Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to medac drug safety at drugsafety@medac.de

References

1. EAU Guidelines 2024, last accessed September 2024
2. Lamm et al, Journal of Clinical Urology Vol. 163, 1124-1129, April 2000

medac code: medacuk D172/09/2024 Date of preparation: September 2024

medac pharma

Stockholm3 test for early detection of Prostate Cancer


Stockholm3 is a blood test for early detection of clinically significant prostate cancer in men aged 45–74 years, with a PSA level of 1.5 ng/ml, or greater, and no previous diagnosis of prostate cancer.



SCAN ME

Key characteristics

- Increased early detection – increased sensitivity
- Increased specificity reduces over testing, unnecessary biopsies by 50% and treatment
- Higher accuracy compared to PSA, PSAD and prostate cancer risk calculator
- Can distinguish between aggressive and benign tumours in a way that PSA testing cannot
- Validated in combination with MRI and in multiple ethnicities
- Shown to detect clinically significant prostate cancers in PSA levels of 1.5–2.9 ng/ml
- Reduces healthcare costs



PROGRAMME

Thursday 14th November 2024

0845-0920	Registration and Arrival Refreshments
0920-0930	Welcome to BAUS Oncology Jon Aning , Southmead Hospital, Bristol and Chair, BAUS Section of Oncology
0930-1105	Session 1: Advances in Renal Cancer Management: Multidisciplinary Perspectives Chairs: Suresh Venugopal , Royal Liverpool University, Alice Thompson , Royal Gwent Hospital and Jim Armitage , Addenbrooke's Hospital, Cambridge
0930-0932	Introduction by Chairs
0932-0947	Novel Imaging Modalities for Characterising Renal Lesions Iztok Caglic , Consultant Radiologist, Cambridge University Hospitals NHS Foundation Trust
0947-0949	Q&A
0949-1003	A Practical and Clinically Relevant Approach to Renal Mass Biopsies Soha El-Sheikh , Pathologist, Royal Free Hospital, London
1003-1005	Q&A
1005-1020	Optimising Active Surveillance for Small Renal Masses: Selection Criteria, Surveillance Protocols and Progression Benchmarks Ravi Barod , Royal Free Hospital, London

PROGRAMME

Thursday 14th November 2024

1020-1022	Q&A
1022-1036	<p>The Interventional Radiologist's Role in Localised and Metastatic Renal Cancers</p> <p>Tze Yuan Chan, Interventional Radiologist, Royal Liverpool and Broadgreen University Hospital NHS Trust</p>
1036-1038	Q&A
1038-1053	<p>Adjuvant Therapy for Resected Primary Renal Cell Carcinoma (RCC): Evidence Base and Indications for High-Risk Relapse Patients</p> <p>Axel Bex, Royal Free Hospital, London</p>
1053-1055	Q&A
1055-1100	Conclusion by Chairs
1100-1105	<p>GenesisCare Commerical Break</p> <p>SABR – A new treatment paradigm for Renal Cancer, Dr Philip Camilleri, Consultant Clinical Oncologists, OUH, Clinical Director Uro-Oncology GenesisCare.</p>
1100-1130	Refreshments, Poster & Exhibition Viewing

PROGRAMME

Thursday 14th November 2024

1130-1250	Session 2: Innovations in Sexual Health, Fertility, and Cancer Management Chairs: Arie Parnham , The Christie NHS Foundation Trust, Manchester and Eleni Anastasiadis , Croydon University Hospital, Surrey
1130-1132	Introduction by Chairs
1132-1147	Improving Sexual Health Outcomes in Prostate Cancer: A Focus on Sexual Minorities Tet Yap , Guy's & Thomas's Hospital, London
1147-1149	Q&A
1149-1204	Fertility Preservation in Testis Cancer Hussain Alnajjar , University College Hospital, London
1204-1206	Q&A
1206-1221	The Dilemma of Small Intermediate Testis Masses - How Should We Manage These? Susan Wong , University Hospitals Birmingham NHS Foundation Trust
1221-1223	Q&A
1100-1130	Is VEILND Going to Take Over Conventional Radical Inguinal Lymphadenectomy in Penile Cancer? Vivek Kumar , Norfolk And Norwich University Hospital
1238-1240	Q&A

PROGRAMME

Thursday 14th November 2024

1240-1245	Conclusion by Chairs
1245-1250	MSD Commercial Break
1250-1345	Lunch, Poster & Exhibition Viewing
1345-1520	Session 3: Innovations and Controversies in Prostate Cancer Management Chairs: Stephanie Guillaumier , NHS Fife, Sarah Prattley , University Hospital of Wales, Cardiff and Ben Lamb , The Royal London Hospital
1345-1347	Introduction by Chairs
1347-1402	Rethinking Active Surveillance: Can We Avoid Prostate Biopsies? Rajan Veeratterapillay , Freeman Hospital, Newcastle
1402-1404	Q&A
1404-1419	Streamlining Prostate Imaging: Is Bi-Parametric MRIs PRIMEd to Save Time? Alexander Ng , Royal Free Hospital, London
1419-1421	Q&A
1421-1436	Decoding Genetic Risk: Essential Somatic and Germline Testing for Urologists Ashwin Sachdeva , The Christie NHS Foundation Trust, Manchester
1436-1438	Q&A

PROGRAMME

Thursday 14th November 2024

1438-1453	Testosterone Replacement Therapy in Prostate Cancer: Is It Safe? Peter Grice , Northampton General Hospital
1453-1455	Q&A
1455-1510	PSMA PET Imaging in Directing Treatment for High-Risk Prostate Cancer Martin Connor , Charing Cross Hospital, London
1510-1512	Q&A
1512-1515	Conclusion by Chairs
1515-1520	Medac Pharma Commercial Break
1520-1545	Refreshments, Poster & Exhibition Viewing
1545-1705	Session 4: Advancements in Urothelial Cancer: Bladder and Upper Tract Innovations Chairs: Alexandra Masson-Lecomte , Saint-Louis Hospital, Paris, Niyati Lobo , Cambridge University Hospitals, Ramprakash Beekhar , Belfast City Hospital

PROGRAMME

Thursday 14th November 2024

1545-1547	Introduction by Chairs
1547-1559	Tackling Recurrent Low-Grade Bladder Cancer After Intravesical MMC and BCG: Finding the Way Forward Lyndon Gommersall , Royal Stoke University Hospital
1559-1601	Q&A
1601-1613	Is there a role for radiotherapy in High Risk NMIBC? Vijay Sangar , Wythenshawe Hospital, Manchester
1613-1615	Q&A
1615-1627	A Risk-Stratified Approach to Diagnostic URS in Suspected UTUC: Outcomes of the IDUNC Audit Bhavan Rai , Freeman Hospital, Newcastle
1627-1629	Q&A
1629-1641	Is Segmental Resection and Distal Ureterectomy an Underutilized Approach in the Management of Upper Tract Urothelial Carcinoma (UTUC)? Alexandra Masson-Lecomte , Saint-Louis Hospital, Paris
1641-1643	Q&A
1643-1655	Building a Multidisciplinary Exenteration Service: The Expanding Role of Cystectomy Surgeons within the NHS Jeremy Oates , The Christie NHS Foundation Trust Manchester
1655-1657	Q&A
1657-1700	Conclusion by Chairs
1700-1705	The Doctors Laboratory Commerical Break

Precision redefined

with MRI-guided
radiotherapy



At GenesisCare we're delivering the most comprehensive stereotactic service in the UK today

- **Effective & non-invasive** Treatment for localised prostate cancer and localised kidney cancer in patients unfit for anaesthetic or who decline surgery
- **Fewer treatments** Renal SABR completed in 1, 3 or 5 sessions
- **Fewer side-effects** Reduces acute GI toxicities vs. traditional methods¹
- **Superior imaging** Clearer soft tissue definition for accurate targeting
- **Automated beam gating** Safe, high-dose delivery to target
- **Expert care** Delivered by leading clinical specialists at our network of 14 state-of-the art outpatient centres

Interested in working with us or referring a patient?
enquiries@genesiscare.co.uk

Reference: 1. Kishan A. et al., Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial. JAMA Oncol. 12 Jan 2023. doi: 10.1001/jamaoncol.2022.6558.

 **GenesisCare**
Experts in cancer care



At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd-uk.com and connect with us @MSDintheUK on [Twitter](#), [LinkedIn](#), [Instagram](#), [YouTube](#) and [Facebook](#).

GALEAS™ Bladder Cancer testing service

A non-invasive, test-to-report, molecular triage testing service for the detection and monitoring of bladder cancer

One urine test, for all stages

	Sensitivity (%)	Specificity (%)	NPV (%)
Cystoscopy	84	86	96
GALEAS Bladder NMIBC	92	86	99
GALEAS Bladder MIBC	92	86	99

Sensitivity analyses for the performance of GALEAS Bladder in the detection of cancer in the 710 patients assessed

New white paper demonstrates GALEAS Bladder surveillance clinical sensitivity

GALEAS Bladder was validated using a cohort of urine samples collected from patients undergoing surveillance cystoscopy for NMIBC disease recurrence.

Of the 268 patients negative on the day of their surveillance cystoscopy, 23 were subsequently diagnosed with bladder cancer recurrence at a future cystoscopy (2-24 months). Of these, 13 were identified as GALEAS Bladder positive at the time of their negative surveillance cystoscopy.



Scan to download
the white paper



Bayer plc aims to develop products that improve people's quality of life. We concentrate on the research and development of innovative drugs and novel therapeutic approaches to prioritise targets and pathways with the potential to impact not just the treatment of common cancers, but rarer cancers as well.

Want to stay up-to-date with the latest information on Bayer's products, services and events? UK healthcare professionals and other relevant UK decision makers can register here to subscribe to electronic communications: <https://pro.bayer.co.uk/>

Visit <https://oncology.bayer.co.uk/> for more information.

PP-PF-ONC-GB-0357

May 2023



PROGRAMME

Friday 15th November 2024

0800-0830	Registration and Arrival Refreshments
0825-0830	Welcome and Introduction of International Guest Vishwanath Hanchanale , Liverpool University Hospitals Foundation Trust
0830-0850	Updates from EAU Guidelines on UTUC Alexandra Masson-Lecomte , Saint-Louis Hospital, Paris
0850-0900	Q&A
0900-1030	Session 5: Masterclass in Urological Surgery: Semi-Live Video Presentations Chairs: Elizabeth Bright , Royal Cornwall Hospital, Truro, Ben Sherwood , Nottingham City Hospital and Vishwanath Hanchanale , Liverpool University Foundation Trust
0900-0902	Introduction
0902-0917	Robotic IVC thrombectomies- The Bristol Experience Salah Al-Buheissi , Southmead Hospital, Bristol
0917-0919	Q&A
0919-0934	Real-Time Surgical Precision: Complete Urethral Preservation and Assessing Margin Status During Radical Prostatectomy Gregory Shaw , University College Hospital, London
0934-0936	Q&A
0936-0951	Mastering Open Retroperitoneal Surgery: A Step-by-Step Approach Edgar Paez-Gueyraud , Freeman Hospital, Newcastle
0951-0953	Q&A

PROGRAMME

Friday 15th November 2024

0953-1008	Robotic Upper Tract Surgery: Tips and Tricks for Navigating Variant Anatomy Raj Nair , Guy's & St Thomas' Hospital, London
1008-1010	Q&A
1010-1023	Early Insights: Single-Port (SP) Robotic Radical Prostatectomy Declan Cahill , Royal Marsden Hospital, London
1023-1025	Conclusion by Chairs
1025-1030	Informed Genomics Commercial Break
1030-1100	Refreshments, Poster & Exhibition Viewing
1100-1210	Session 6: Today's Stars and Tomorrow Leaders: Celebrating Trainee Excellence Chairs: Omar El-Taji , The Christie Hospital and Salford Royal NHS Trust, Manchester and Marie Edison , Chelsea and Westminster Hospital, London
1100-1102	Introduction by Chairs
1102-1114	Leading the Charge: Insights from a Young PI in Oncology Trials Cameron Alexander , Colchester General Hospital
1114-1126	Surgical Frontiers: Expanding Global Impact Through UroLink Johann Boaz , Charing Cross Hospital, London
1126-1138	Leadership in Action: Lessons from a Seasoned Chair Sarika Nalagatla , Frimley Park NHS Foundation Trust
1138-1150	Achieving Gold: Balancing Sub-Specialty Excellence with FRCS Success Nick Simson , St Georges NHS Foundation Trust

PROGRAMME

Friday 15th November 2024

1150-1202 BAUS Oncology and BSoT Uro-Oncology Fellowship Award
Omar El-Taji, The Christie Hospital and Salford Royal NHS Trust, Manchester and BSoT Representative for the Section of Oncology and **Marie Edison**, Chelsea and Westminster Hospital, London.

1202-1205 Conclusion by Chairs

1205-1210 Bayer Industry Commercial Break

1210-1310 **Session 7: Abstract Podium Presentations**
Chairs: **Kenneth MacKenzie**, Sunderland Royal Hospital, **Eva Bolton** Charing Cross Hospital, London and **Will Green**, Nottingham City Hospital

Presenters:

1. Raiees Malla
2. Hari Vigneswaran (Stockholm 3)
3. Hari Vigenwaran (STHLM3 Trial)
4. Jacob Wilson
5. Yasmin Abu Ghanem
6. Luke Glover
7. Nikhil Mayor (Prostate Cancer Screening)
8. Rebecca Smith
9. Stephanie Smith
10. Nikhil Maypr (Immunohistochemistry)

1310-1315 Aquilant Commercial Break

1315-1400 Lunch, Poster & Exhibition Viewing

PROGRAMME

Friday 15th November 2024

- 1400-1505 **Session 8: Navigating the Psychological Dimensions of Complex Uro-Oncology | Supported by The Urology Foundation**
Chairs: **Ben Ayres**, St George's Hospital, London and **Sophia Hobson**, Clinical Nurse Specialist for Prostate Cancer, St George's Hospital, London
- Speakers:
Ben Ayres, St George's Hospital, London
Sophia Hobson, Clinical Nurse Specialist for Prostate Cancer, St George's Hospital, London
Asanga Fernando, Consultant Cancer Liaison Psychiatrist, St George's Hospital, London
Jenna Love, Clinical Psychologist, St George's Hospital, London
Guy Oliver-Watts, Actor
- A session exploring the unmet psychological needs of patients with urological cancers, with practical suggestions on what Urologists and Nurse Specialists can do, explored through live role-play.
- 1500-1505 MSD/AZ Commercial Break
- 1505-1530 Refreshments, Poster & Exhibition Viewing
- 1530-1645 **Session 9: Audit and Research**
Chairs: **Rakesh Heer**, Charing Cross Hospital, London, **Prabrakaran Rajan**, St Bartholomew's Hospital and **Shiv Pandian**, North Middlesex Hospital, London
- 1530-1532 Introduction by Chairs

PROGRAMME

Friday 15th November 2024

1532-1552	Best of Uro-Oncology Papers for 2024 BJUI Alastair Lamb,
1552-1602	Prostate Cancer Noel Clarke, The Christie NHS Foundation Trust, Manchester
1602-1612	Kidney Cancer Raghav Varma, City Hospital Birmingham
1612-1622	Trials Updates Gokul Kandaswamy, Morriston Hospital, Swansea
1622-1625	Conclusion by Chairs
1625-1635	Closing Remarks and Future of BAUS Oncology Bhavan Rai, Freeman Hospital, Newcastle